Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. Many readers responded to our data-driven coverage of how ethical and religious directives issued by the U.S. Conference of Catholic Bishops affect care options at Catholic and Catholic-affiliated hospitals in the […]

Supernus Pharmaceuticals said on Monday the U.S. FDA declined to approve its drug-device combination to treat movement-related symptoms of Parkinson’s disease, sending its shares down 9% in early trade. This is the second time the regulator has refused to approve, dealing a… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]

Synchron Inc, a rival to Elon Musk’s Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company’s chief executive told Reuters. Synchron on Monday plans to launch an… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]